After a strong morning rally, BioNTech stock price stabilizes at $92. Apparently, government officials are to recommend to an influential healthcare panel that such products are linked to a number of fatalities. "Just their name was made based off the pandemic and the vaccines that they very quickly brought to people around the world to help get us through that period of time," said Evercore ISI analyst Cory Kasimov. "But the approach they're taking now and the outlook for these two companies is distinctly different at this point." In today’s pre-market, BioNTech stock price is quoted at $92.15, up 0.8%, with trading chatter focused on potential EU vaccine contracts renewal. Fund managers are positioning portfolios to capture mid-cap biotech growth amid broader healthcare sector rotations.
